Author

Jonathan Harris

Observed names: J. Harris, J.C. Harris, Jonathan Harris (21226153)

Institution: NRG Oncology

Observed institutions: American College of Radiology, Fox Chase Cancer Center, Maimonides Medical Center, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, University of California, San Francisco, Medical College of Wisconsin, RTOG Foundation, Thomas Jefferson University Hospital, Johns Hopkins Medicine, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Moffitt Cancer Center, Bellevue Hospital Center, Johns Hopkins Hospital, NRG Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, The Ohio State University

ORCID: 0000-0003-0571-7839

Observed ORCID: 0000-0003-0571-7839

OpenAlex ID: A5034026762

Tobacco Smoking and Increased Risk of Death and Progression for Patients With p16-Positive and p16-Negative Oropharyngeal Cancer

2012 · Maura L. Gillison, Qiang Zhang, et al. · Journal of Clinical Oncology · 487

Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial

2023 · Eric J Sherman, Jonathan Harris, et al. · The Lancet Oncology · 42

Kaposi Sarcoma Mimicking Acute Flare of Ulcerative Colitis

2017 · Vivek Kumar, Parita Soni, et al. · Journal of Investigative Medicine High Impact Case Reports · 17

Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer

2025 · Mitchell Machtay, Pedro A. Torres-Saavedra, et al. · Journal of Clinical Oncology · 14

Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504

2022 · Maura L. Gillison, Robert L. Ferris, et al. · International Journal of Radiation Oncology*Biology*Physics · 13

Antineutrophilic Cytoplasmic Antibody Positive Vasculitis Associated with Methimazole Use

2015 · Deep Shikha, Jonathan Harris, et al. · Case Reports in Endocrinology · 11

Adenomyomatous hyperplasia of distal common bile duct: a case report and review of the literature

2018 · Paul Chandler, Jonathan Harris, et al. · Journal of Surgical Case Reports · 9

Primary Effusion Lymphoma with Central Nervous System Involvement in an HIV-Negative Homosexual Male

2012 · Oluyomi E. Kabiawu-Ajise, Jonathan Harris, et al. · Acta Haematologica · 8

Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer

2024 · Li Guan, Pedro A. Torres-Saavedra, et al. · Clinical Cancer Research · 7

NRG-DT001 phase Ib trial of neoadjuvant navtemadlin (previously AMG232 and KRT232) concurrent with preoperative radiotherapy in wild-type p53 soft tissue sarcoma of the extremity and body wall.

2022 · Meng Xu Welliver, Pedro A. Torres-Saavedra, et al. · Journal of Clinical Oncology · 3

Phase II trial of concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): Results of RTOG 9911

2004 · C. J. Langer, J. Harris, et al. · Journal of Clinical Oncology · 3

Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology RTOG 9911

2025 · Corey J. Langer, Jonathan Harris, et al. · International Journal of Radiation Oncology*Biology*Physics · 1

Supplementary Table S9 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma

2026 · Lazar Vujanovic, Pedro Torres-Saavedra, et al.

Supplementary Figure S1 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma

2026 · Lazar Vujanovic, Pedro Torres-Saavedra, et al.

Supplementary Table S5 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma

2026 · Lazar Vujanovic, Pedro Torres-Saavedra, et al.

Supplementary Figure S3 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma

2026 · Lazar Vujanovic, Pedro Torres-Saavedra, et al.

Supplementary Table S4 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma

2026 · Lazar Vujanovic, Pedro Torres-Saavedra, et al.

Supplementary Table S2 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma

2026 · Lazar Vujanovic, Pedro Torres-Saavedra, et al.

Supplementary Figure S2 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma

2026 · Lazar Vujanovic, Pedro Torres-Saavedra, et al.

Supplementary Table S7 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma

2026 · Lazar Vujanovic, Pedro Torres-Saavedra, et al.

Supplementary Table S1 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma

2026 · Lazar Vujanovic, Pedro Torres-Saavedra, et al.

Data from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma

2026 · Lazar Vujanovic, Pedro Torres-Saavedra, et al.

Supplementary Table S6 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma

2026 · Lazar Vujanovic, Pedro Torres-Saavedra, et al.

Supplementary Figure S5 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma

2026 · Lazar Vujanovic, Pedro Torres-Saavedra, et al.

Supplementary Table S3 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma

2026 · Lazar Vujanovic, Pedro Torres-Saavedra, et al.

Works count: 56

Citation count: 615

H-index: 8

I10-index: 6